Vlad Coric

Chief Executive Officer
Biohaven

Dr. Vlad Coric is the CEO of Biohaven. In his over seven years as CEO of Biohaven, Dr. Coric led the company in the pursuit of its bold vision from an entrepreneurial start-up into a modern, publicly traded company listed on the NYSE with the mission of advancing novel medications to underserved patients. His leadership translated into dramatic growth for the company, from initial pre-money valuation of about $6M to the sale of the company for $13B in total considerations.

Dr. Coric has over 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology, and immuno-oncology. He has been involved in multiple drug development programs, including marketed drugs, or filed NDAs such as Nurtec ODT (rimegepant; oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor), and Sunvepra® (asunaprevir; NS3 inhibitor).

Dr. Coric earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree. He was named one of the Top 25 Healthcare Technology Leaders of Connecticut for 2022 by The Healthcare Technology Report. He was the recipient of the Ernst & Young Entrepreneur of the Year 2018 Award in the NY region.